These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ Menopause; 2008; 15(2):248-55. PubMed ID: 17693902 [TBL] [Abstract][Full Text] [Related]
5. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Scarabin PY; Alhenc-Gelas M; Plu-Bureau G; Taisne P; Agher R; Aiach M Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3071-8. PubMed ID: 9409295 [TBL] [Abstract][Full Text] [Related]
6. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Zegura B; Guzic-Salobir B; Sebestjen M; Keber I Menopause; 2006; 13(4):643-50. PubMed ID: 16837886 [TBL] [Abstract][Full Text] [Related]
7. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens]. Winkler UH; Krämer R; Kwee B; Schindler AE Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837 [TBL] [Abstract][Full Text] [Related]
8. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733 [TBL] [Abstract][Full Text] [Related]
9. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study. Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753 [TBL] [Abstract][Full Text] [Related]
10. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. Koh KK; Mincemoyer R; Bui MN; Csako G; Pucino F; Guetta V; Waclawiw M; Cannon RO N Engl J Med; 1997 Mar; 336(10):683-90. PubMed ID: 9041098 [TBL] [Abstract][Full Text] [Related]
11. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Sumino H; Ichikawa S; Sawada Y; Sakamoto H; Kumakura H; Takayama Y; Sakamaki T; Kurabayashi M Thromb Res; 2005; 115(5):359-66. PubMed ID: 15733968 [TBL] [Abstract][Full Text] [Related]
12. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study. Fait T; Vrablik M; Zizka Z; Kostirova M Gynecol Obstet Invest; 2008; 65(1):47-51. PubMed ID: 17713346 [TBL] [Abstract][Full Text] [Related]
13. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity. Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323 [TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women. Callejon DR; Franceschini SA; Montes MB; Toloi MR Maturitas; 2005; 52(3-4):249-55. PubMed ID: 16257613 [TBL] [Abstract][Full Text] [Related]
15. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Post MS; van der Mooren MJ; van Baal WM; Blankenstein MA; Merkus HM; Kroeks MV; Franke HR; Kenemans P; Stehouwer CD Am J Obstet Gynecol; 2003 Nov; 189(5):1221-7. PubMed ID: 14634544 [TBL] [Abstract][Full Text] [Related]
16. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women. Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143 [TBL] [Abstract][Full Text] [Related]
17. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Kroon UB; Silfverstolpe G; Tengborn L Thromb Haemost; 1994 Apr; 71(4):420-3. PubMed ID: 8052956 [TBL] [Abstract][Full Text] [Related]
18. Circulating concentrations of hemostatic factors and two "steroid sensitive proteins" during oral hormone replacement therapy in women with coronary heart disease. Pripp U; Schenck-Gustafsson K; Landgren BM; Carlström K Scand J Clin Lab Invest; 2004; 64(7):659-65. PubMed ID: 15513323 [TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. Chu MC; Cushman M; Solomon R; Lobo RA Am J Obstet Gynecol; 2008 Nov; 199(5):526.e1-7. PubMed ID: 18511016 [TBL] [Abstract][Full Text] [Related]
20. Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women. Saucedo R; Basurto L; Zarate A; Martínez C; Hernandez M; Galván R Gynecol Obstet Invest; 2007; 64(2):61-4. PubMed ID: 17264514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]